Truist raised the firm’s price target on iRhythm to $115 from $100 and keeps a Buy rating on the shares. Truist views the setup into 2024 is positive and sees a number of drivers that can accelerate revenue growth next year, with further levers into 2025 to extend that momentum, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- iRhythm just upgraded at Citi, here’s why
- Citi gets more bullish on iRhythm, upgrades shares
- iRhythm announces results of new retrospective analysis on ECG monitoring
- New Research Presented at American Heart Association’s 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure Hospitalization
- iRhythm price target lowered to $108 from $140 at Needham
